• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Negl Trop Dis . Genomic and epidemiological characteristics of SARS-CoV-2 in Africa

tetano

Editor, Senior Moderator
PLoS Negl Trop Dis


. 2021 Apr 26;15(4):e0009335.
doi: 10.1371/journal.pntd.0009335. Online ahead of print.
Genomic and epidemiological characteristics of SARS-CoV-2 in Africa


Jones Lamptey[SUP] 1 2 3 [/SUP], Favour Oluwapelumi Oyelami[SUP] 4 [/SUP], Michael Owusu[SUP] 1 2 3 [/SUP], Bernard Nkrumah[SUP] 5 [/SUP], Paul Oluwagbenga Idowu[SUP] 6 [/SUP], Enoch Appiah Adu-Gyamfi[SUP] 7 [/SUP], Armin Czika[SUP] 8 [/SUP], Philip El-Duah[SUP] 9 [/SUP], Richmond Yeboah[SUP] 3 [/SUP], Augustina Sylverken[SUP] 3 10 [/SUP], Oluwatayo Israel Olasunkanmi[SUP] 11 [/SUP], Ellis Owusu-Dabo[SUP] 12 [/SUP], Christian Drosten[SUP] 9 [/SUP], Yaw Adu-Sarkodie[SUP] 2 [/SUP]



Affiliations

Abstract

Since late 2019, the coronavirus disease 2019 (COVID-19) outbreak, caused by SARS-CoV-2, has rapidly evolved to become a global pandemic. Each country was affected but with a varying number of infected cases and mortality rates. Africa was hit late by the pandemic but the number of cases rose sharply. In this study, we investigated 224 SARS-CoV-2 genome sequences from the Global Initiative on Sharing Avian Influenza Data (GISAID) in the early part of the outbreak, of which 69 were from Africa. We analyzed a total of 550 mutations by comparing them with the reference SARS-CoV-2 sequence from Wuhan. We classified the mutations observed based on country and region, and afterwards analyzed common and unique mutations on the African continent as a whole. Correlation analyses showed that the duo variants ORF1ab/RdRp 4715L and S protein 614G variants, which are strongly linked to fatality rate, were not significantly and positively correlated with fatality rates (r = -0.03757, P = 0.5331 and r = -0.2876, P = 0.6389, respectively), although increased number of cases correlated with number of deaths (r = 0.997, P = 0.0002). Furthermore, most cases in Africa were mainly imported from American and European countries, except one isolate with no mutation and was similar to the original isolate from Wuhan. Moreover, unique mutations specific to countries were identified in the early phase of the outbreak but these mutations were not regional-specific. There were common mutations in all isolates across the continent as well as similar isolate-specific mutations in different regions. Our findings suggest that mutation is rapid in SARS-CoV-2 in Africa and although these mutations spread across the continent, the duo variants could not possibly be the sole cause of COVID-19 deaths in Africa in the early phase of the outbreak.
 
Back
Top Bottom